Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: A Dutch TEAM trial analysis

References

• Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: A nested case-control study. J Natl Cancer Inst 2011;103: 744–52.
   PubMed Web of Science ®Google Scholar
• Kim J, Han W, Moon HG, Ahn SK, Shin HC, You JM, et al. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Res 2012;14:R102.
   PubMed Web of Science ®Google Scholar
• Li J, Humphreys K, Eriksson L, Edgren G, Czene K, Hall P. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer. J Clin Oncol 2013;31:2249–56.
   PubMed Web of Science ®Google Scholar
• Sandberg ME, Li J, Hall P, Hartman M, Dos-Santos-Silva I, Humphreys K, et al. Change of mammographic density predicts the risk of contralateral breast cancer: A case-control study. Breast Cancer Res 2013;15:R57.
   PubMed Web of Science ®Google Scholar
• Ko KL, Shin IS, You JY, Jung SY, Ro J, Lee ES. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients. Breast Cancer Res Treat 2013;142:559–67.
   PubMed Web of Science ®Google Scholar
• Wolfe JN. Breast patterns as an index of risk for developing breast cancer. AJR Am J Roentgenol 1976;126:1130–7.
   PubMed Web of Science ®Google Scholar
• Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB et al. Quantitative classification of mammographic densities and breast cancer risk: Results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995; 87:670–5.
   PubMed Web of Science ®Google Scholar
• McCormack VA, Dos Santos Silva, I. Breast density and parenchymal patterns as markers of breast cancer risk: A meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15:1159–69.
   PubMed Web of Science ®Google Scholar
• Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA. Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control 2000;11:653–62.
   PubMed Web of Science ®Google Scholar
• Grove JS, Goodman MJ, Gilbert FI, Jr., Mi MP. Factors associated with mammographic pattern. Br J Radiol 1985; 58:21–5.
   PubMed Web of Science ®Google Scholar
• Atkinson C, Warren R, Bingham SA, Day NE. Mammographic patterns as a predictive biomarker of breast cancer risk: Effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 1999;8:863–6.
   PubMed Web of Science ®Google Scholar
• Brisson J, Brisson B, Cote G, Maunsell E, Berube S, Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 2000;9:911–5.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, et al.Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007;99:272–82.
   PubMed Web of Science ®Google Scholar
• Cigler T, Tu D, Yaffe MJ, Findlay B, Verma S, Johnston D, et al. A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Res Treat 2010;120:427–35.
   PubMed Web of Science ®Google Scholar
• Cigler T, Richardson H, Yaffe MJ, Fabian CJ, Johnston D, Ingle JN, et al. A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. Breast Cancer Res Treat 2011;126:453–61.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Warren R, Pinney L, Warwick J, Howell A. The effect of anastrozole, tamoxifen or a combination of both drugs on mammographic breast density in post menopausal women with breast cancer. Breast Cancer Res Treat 2006;SABCS 2006, abstract no 5033.
   PubMed Web of Science ®Google Scholar
• Prowell TM, Blackford AL, Byrne C, Khouri NF, Dowsett M, Folkerd E, et al. Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer Prev Res (Phila) 2011; 4:1993–2001.
   PubMed Web of Science ®Google Scholar
• Vachon CM, Ingle JN, Suman VJ, Scott CG, Gottardt H, Olson JE, et al. Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen. Breast 2007;16:204–10.
   PubMed Web of Science ®Google Scholar
• Vachon CM, Suman V, Brandt KR, Kosel ML, Buzdar AU, Olson JE, et al. Mammographic breast density response to aromatase inhibition. Clin Cancer Res 2013; 19:2144–53.
   PubMed Web of Science ®Google Scholar
• van de Velde CJH, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomised phase 3 trial. Lancet 2011;377:321–31.
   PubMed Web of Science ®Google Scholar
• Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121–30.
   PubMed Web of Science ®Google Scholar
• Li J, Czene K, Brauch H, Schroth W, Saladores P, Li Y, et al. Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment. Breast Cancer Res 2013;15:R93.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sestak I, Cella D, Fallowfield L. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: A retrospective analysis of the ATAC trial. Lancet Oncol 2008;9:1143–8.
   PubMed Web of Science ®Google Scholar
• Lienart V, Carly B, Kang X, Guzy L, Sajovitz AM, Liebens F. Effect of preventive hormonal therapy on breast density: A systematic qualitative review. Sci World J 2014;2014:942386.
   Web of Science ®Google Scholar
• Geisler J. Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole-of clinical importance? Br J Cancer 2011;104:1059–66.
   PubMed Web of Science ®Google Scholar
• Miller WR, Bartlett JMS, Brodie AM, Brueggemeier RW, di Salle E, Lonning PE, et al. Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 2008;13:829–37.
   PubMed Web of Science ®Google Scholar
• Kallenberg MG, Lokate M, van Gils CH, Karssemeijer N. Automatic breast density segmentation: An integration of different approaches. Phys Med Biol 2011;56:2715–29.
   PubMed Web of Science ®Google Scholar
• Boyd NF, Martin LJ, Bronskill M, Yaffe MJ, Duric N, Minkin S. Breast tissue composition and susceptibility to breast cancer. J Natl Cancer Inst 2010;102:1224–37.
   PubMed Web of Science ®Google Scholar
• van Engeland S, Snoeren PR, Huisman H, Boetes C, Karssemeijer N. Volumetric breast density estimation from full-field digital mammograms. IEEE Trans Med Imaging 2006;25:273–82.
   PubMed Web of Science ®Google Scholar
• Lokate M, Kallenberg MG, Karssemeijer N, Van den Bosch MA, Peeters PH, van Gils CH. Volumetric breast density from full-field digital mammograms and its association with breast cancer risk factors: A comparison with a threshold method. Cancer Epidemiol Biomarkers Prev 2010;19: 3096–105.
   PubMed Web of Science ®Google Scholar